On the stock market since 2009, it operates in the world of health and science. It has 13,528 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 74% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 8% a year on average.
The company sells $2.3B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $0.05 per share each year — regular cash for whoever holds the stock.
A loss of $320.3M against $2.3B in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, GRRMF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GRRMF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.